Product Description
Ovoca Bio is currently developing Orenetide (BP-101), a novel synthetic peptide with significant potential for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. (Sourced from: https://ovocabio.com/pipeline/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Topical, Nasal
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Ivix LLX
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Other
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03102489 |
BP101-HV02 | P1 |
Completed |
Healthy Volunteers |
2017-06-21 |
2020-02-12 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
ACTRN12620001356954 |
ACTRN12620001356954 | P2 |
Terminated |
Other |
2022-07-28 |
2026-02-15 |
Treatments |
|
NCT03080298 |
BP101-SD01 | P2 |
Completed |
Other |
2017-04-04 |
2019-03-21 |
Treatments |
|
NCT03463707 |
BP101-SD02-RUS | P3 |
Completed |
Other |
2018-11-26 |
11% |
2020-02-12 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |